Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JPMA Proposes Specific Measures for Growth Strategy
May 31, 2010
- Korosho Completes Hearings of Wholesalers on Changes in Business Practice
May 31, 2010
- Mr Shoda Elected President of Industry's FTC
May 31, 2010
- Pletaal No. 1 on HP Market, Ecard on GP Market
May 31, 2010
- Sales of Top-8 Domestic Companies Up 2.7%
May 31, 2010
- Shionogi Returns Moxifloxacin to Bayer Yakuhin
May 31, 2010
- Taisho: Sales of Ethical Drugs Up 4.8% to ¥99,590 Mil.
May 31, 2010
- Bufexamac to Be Withdrawn From EU Market
May 31, 2010
- Ono: Sales Down 0.4% Due to Competition with Generics
May 31, 2010
- Nippon Universal Renamed Zydus Pharma
May 31, 2010
- Santen: Sales Up 8.8% Driven by Tapros, Hyalein
May 31, 2010
- Sawai: Sales Exceed ¥50.0 Bil. Benchmark
May 31, 2010
- Kyorin: Mainstay Products Drive Sales Up 9.8% to ¥99.8 Bil.
May 31, 2010
- Towa: Strong Growth in Sales to Pharmacies Drive Business
May 31, 2010
- Kaken: Sales Up 2.5% to ¥85 Bil. Driven by Artz
May 31, 2010
- Nippon Chemiphar: Sales, Profits Up Driven by Generics
May 31, 2010
- Mochida: Sales Up 4.5% to ¥78.5 Bil. Driven by Epadel
May 31, 2010
- Rufinamide to Enter PIII in Japan: Eisai
May 31, 2010
- Daiichi Sankyo Voluntarily Recalls Amplit Tablets 25 mg
May 24, 2010
- Erbitux Makes Hepatic Metastasis of Colon Cancer Curable: Prof. Sugihara
May 24, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…